It is not yet clear when that national security investigation will end, and if and how tariffs on pharmaceuticals will be ...

A February executive order on pharmaceutical price transparency does nothing to change the incentives that keep costs opaque.

Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug ...

Compounded GLP-1s are no longer to be sold following the FDA announcement that the shortage of semaglutide and tirzepatide ended.

The issue is nothing new, but it has been receiving more attention as the Trump administration, lawmakers and community ...

his company would be transparent with consumers about the cost of tariffs and broker fees and pass them "directly" on to customers. There would be no way for Cost Plus Drugs to "eat" the costs.

If an accused sets up a claim of his false implication on the ground that no sensible person would carry contraband in a ...